After Hours
There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours.
Stocks Info
This NASDAQ-listed company operates within the Biotechnology industry segment, falling under the Healthcare sector. The current market capitalization of Ultragenyx Pharmaceutical Inc is $2.23B. A total of 3.95 million shares were traded on the day, compared to an average of 1.95M shares.
In the most recent transaction, Horn Howard sold 3,150 shares of RARE for 22.84 per share on Jan 02 ’26. After the transaction, the Chief Financial Officer now owns 91,996 company shares. In a previous transaction on Jan 02 ’26, HOWARD HORN bought 3,150 shares at 22.84 per share.
Among the insiders who sold shares, Huizenga Theodore Alan disposed of 85 shares on Dec 29 ’25 at a per-share price of $34.38. This resulted in the SVP, Chief Accounting Officer holding 50,450 shares of RARE after the transaction. In another insider transaction, Horn Howard sold 3,081 shares at $36.38 per share on Dec 10 ’25. Company shares held by the Chief Financial Officer now total 95,146.
Even though price targets are rarely accurate, they do tend to exert some kind of influence from time to time and are often considered important by markets. In terms of 52-week highs and lows, RARE has a high of $46.50 and a low of $18.41.
As of this writing, RARE has an earnings estimate of -$1.21 per share for the current quarter. EPS was calculated based on a consensus of 12.0 estimates, with a high estimate of -$0.71 per share and a lower estimate of -$1.87. The company reported an EPS of -$1.39 in the last quarter
Balance Sheet Annually/Quarterly
In a balance sheet, you can see what assets and liabilities the company has, as well as how much equity investors have invested. These figures can be used to calculate a company’s financial ratios to give investors a better idea of its prospects. RARE’s latest balance sheet shows that the firm has $740.20M in Cash & Short Term Investments as of fiscal 2021. There were $41.97M in debt and $181.37M in liabilities at the time. Its Book Value Per Share was $0.10, while its Total Shareholder’s Equity was $922.56M.
Analysts Opinion
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for RARE is Buy with a score of 4.77.
